Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis

被引：0
|
作者：
Silverberg, Jonathan, I [1 ]
Bieber, Thomas [2 ,3 ]
Paller, Amy [4 ]
Beck, Lisa A. [5 ]
Kamata, Masahiro [6 ]
Puig, Luis [7 ]
Wiseman, Marni [8 ,9 ]
Ezzedine, Khaled [10 ]
Foley, Peter [11 ]
Johansson, Erin [12 ]
Dossenbach, Martin [12 ]
Akmaz, Bulent [13 ]
Casillas, Marta [12 ]
Karlsson, Andrei [14 ]
Chovatiya, Raj [15 ]
机构：
[1] George Washington Univ, Dept Dermatol, Sch Med & Hlth Sci, Washington, DC USA
[2] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany
[3] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland
[4] Northwestern Univ, Dept Dermatol, Chicago, IL USA
[5] Univ Rochester, Med Ctr, Rochester, NY USA
[6] Teikyo Univ, Sch Med, Dept Dermatol, Tokyo, Japan
[7] Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain
[8] Univ Manitoba, Sect Dermatol, Winnipeg, MB, Canada
[9] SKiNWISE Dermatol, Winnipeg, MB, Canada
[10] Univ Paris Est, EpiDermE, Paris, France
[11] Skin Hlth Inst, Melbourne, Vic, Australia
[12] Eli Lilly & Co, Indianapolis, IN USA
[13] Almirall SA, Barcelona, Spain
[14] Costello Med, London, England
[15] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
atopic dermatitis; lebrikizumab; network meta-analysis; targeted systemic therapy;
D O I：
10.1093/bjd/ljae266.014
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
630
引用
收藏
页码：15 / 16
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
    Li, Ling
    Yu, Jiajun
    Chen, Baoqing
    Guo, Ying
    Yang, Yufeng
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [22] Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, Emma
    Weidinger, Stephan
    Simpson, Eric
    Gooderham, Melinda
    Irvine, Alan
    Spelman, Lynda
    Silverberg, Jonathan
    Elmaraghy, Hany
    DeLuca-Carter, Louise
    Piruzeli, Maria Lucia Buziqui
    Hu, Chaoran
    Yang, Fan Emily
    Pierce, Evangeline
    Bardolet, Laia
    Thaci, Diamant
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II3 - II4
  • [23] MAINTENANCE OF LEBRIKIZUMAB EFFICACY IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS WITH STABLE ASTHMA CONTROL
    Mehta, V.
    Worm, M.
    Chiesa, Z.
    Natalie, C.
    Dawson, Z.
    Zhong, J.
    Diemert, S.
    Boguniewicz, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S89 - S90
  • [24] Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis
    Silverberg, Jonathan I.
    Hong, H. Chih-ho
    Thyssen, Jacob P.
    Calimlim, Brian M.
    Joshi, Avani
    Teixeira, Henrique D.
    Collins, Eric B.
    Crowell, Marjorie M.
    Johnson, Scott J.
    Armstrong, April W.
    DERMATOLOGY AND THERAPY, 2022, 12 (05) : 1181 - 1196
  • [25] Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis
    Jonathan I. Silverberg
    H. Chih-ho Hong
    Jacob P. Thyssen
    Brian M. Calimlim
    Avani Joshi
    Henrique D. Teixeira
    Eric B. Collins
    Marjorie M. Crowell
    Scott J. Johnson
    April W. Armstrong
    Dermatology and Therapy, 2022, 12 : 1181 - 1196
  • [26] Comparative effectiveness of targeted therapies with topical corticosteroids for moderate-to-severe atopic dermatitis: Systematic review and network meta-analysis
    Thyssen, J.
    Silverberg, J.
    Armstrong, A.
    Calimlim, B.
    Teixeira, H.
    Collins, E.
    Crowell, M.
    Johnson, S.
    Hong, H. Chih-ho
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 16 - 16
  • [27] Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
    Huang, Yuanjie
    Cai, Limin
    Wu, Xuerui
    Chen, Chen
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2023, 40 (06): : 725 - 733
  • [28] Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    Silverberg, Jonathan I.
    Guttman-Yassky, Emma
    Thaci, Diamant
    Irvine, Alan D.
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric L.
    Chu, Chia-Yu
    Liu, Zhuqing
    Lima, Renata Gontijo
    Pillai, Sreekumar G.
    Seneschal, Julien
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (12): : 1080 - 1091
  • [29] Improved and cleared facial and hand dermatitis with lebrikizumab in patients with moderate-to-severe atopic dermatitis
    Murase, Jenny E.
    Chovatiya, Raj
    Strowd, Lindsay
    Thyssen, Jacob P.
    Bangert, Christine
    Atwater, Amber Reck
    Gallo, Gaia
    Bardolet, Laia
    Yang, Fan
    Zhong, Jinglin
    Staumont-Salle, Delphine
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [30] MAINTENANCE OF LEBRIKIZUMAB EFFICACY IN PATIENTS WITH MODERATE -TO -SEVERE ATOPIC DERMATITIS AND ATOPIC COMORBIDITIES
    Sher, E.
    Golant, A.
    DeBruin-Weller, M.
    Dawson, Z.
    Atwater, A.
    Zhong, J.
    Carrascosa, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S9 - S9
12345